Journal article
Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis
Abstract
PURPOSE: The risks and benefits of continuing bisphosphonate therapy beyond 5 years in patients with primary osteoporosis have not been well established.
METHODS: We searched MedLine, EMBase, CENTRAL, CINAHL, and AgeLine prior to February 2010. Bibliographies were also searched and experts in the field contacted. The ProQuest Dissertations and Theses database and relevant conference proceedings were searched to identify unpublished or ongoing …
Authors
Fraser L-A; Vogt KN; Adachi JD; Thabane L
Journal
Therapeutics and Clinical Risk Management, Vol. 7, No. 0, pp. 157–166
Publisher
Taylor & Francis
Publication Date
2011
DOI
10.2147/tcrm.s19385
ISSN
1176-6336